Patents Represented by Attorney Donald G. Lewis
-
Patent number: 5750691Abstract: Transformations of taxol, baccatin III and of 10-deacetyl baccatin III provide access to novel taxol analogs and key intermediates thereto.Type: GrantFiled: August 7, 1995Date of Patent: May 12, 1998Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
-
Patent number: 5733757Abstract: Antibodies that catalyze the aldol reaction are generated by immunization with a reactive compound that covalently traps a Lysine (Lys) residue in the binding pocket of the antibody by formation of a stable vinylogous amide, i.e., a covalent antibody/hapten complex. The resultant catalytic antibodies employ a catalytic mechanism which mimics the catalytic mechanism employed by natural class I aldolase enzymes.Type: GrantFiled: December 15, 1995Date of Patent: March 31, 1998Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Richard A. Lerner, Juergen Wagner
-
Patent number: 5731334Abstract: C-2'-methylpyridinium acetates (MPA)-taxol and C-2'-methylpyridinium acetates (MPA)-taxotere are prodrugs having good aqueous solubility, low toxiticity and high anti-minor activity. These prodrugs are administered to patients for treating minors. Adminstration may be by injection or infusion.Type: GrantFiled: October 27, 1995Date of Patent: March 24, 1998Assignee: The Scripps Research InstituteInventor: Wolfgang Wrasidlo
-
Patent number: 5723598Abstract: The present invention describes an encoded combinatorial chemical library comprised of a plurality of bifunctional molecules having both a chemical polymer and an identifier oligonucleotide sequence that defines the structure of the chemical polymer. Also described are the bifunctional molecules of the library, and methods of using the library to identify chemical structures within the library that bind to biologically active molecules in preselected binding interactions.Type: GrantFiled: June 18, 1996Date of Patent: March 3, 1998Assignee: The Scripps Research InstituteInventors: Richard Lerner, Kim Janda, Sydney Brenner
-
Patent number: 5614615Abstract: Sialyl Lewis X mimetics incorporating fucopeptides are synthesized and shown to mimic the configuration and essential functional groups of sialyl Lewis X in space. The fucopeptides exhibit substantially the same biological activity as sialyl Lewis X in the E-selectin binding assay and can be employed for blocking neutrophil inflammatory conditions.Type: GrantFiled: August 25, 1995Date of Patent: March 25, 1997Assignee: The Scripps Research InstituteInventor: Chi-Huey Wong
-
Patent number: 5612380Abstract: Sleep may be induced by administration of fatty acid primary amides, including cis-9,10-octadecenoamide. Furthermore, sleep deprivation may be assayed by analyzing cerebrospinal fluid with respect to the presence of fatty acid primary amides, including cis-9,10-octadecenoamide. The presence of cis-9,10-octadecenoamide in cerebrospinal fluid is correlated with comparative sleep deprivation.Type: GrantFiled: January 5, 1995Date of Patent: March 18, 1997Assignee: The Scripps Research InstituteInventors: Richard A. Lerner, Dale Boger, Ben Cravatt, Gary E. Siuzdak, Steven J. Henriksen
-
Patent number: 5608087Abstract: Alkaline sensitive protaxol is water soluble and is hydrolyzed at physiological (alkaline) pH to render the native taxol structure and the native taxol activity. Protaxol compositions include 2'- and/or 7-O-ester derivatives of taxol and/or 2'- and/or 7-O-carbonate derivatives taxol. Protaxol has a formula as follows: ##STR1## wherein R.sup.1 and R.sup.2 are each H or a radical selected from the group consisting of --CO--(CH.sub.2).sub.m --X--(CH.sub.2).sub.n --COZ and --COO--(CH.sub.2).sub.o --Y--Ar, and wherein m, n, and o are each an integer of 1 to 3; X is O, S, NH, SO, or SO.sub.2 ; Y is S, SO or SO.sub.2 ; Ar is phenyl or substituted phenyl wherein the substituent is halo, amino, nitro or N,N-dialkylamino having 1 to 4 carbons in each of the alkyl groups; and Z is OH, OR.sup.3, SR.sup.3 or NR.sup.4 R.sup.5 wherein R.sup.3 is alkyl containing 1 to 4 carbons and R.sup.4 and R.sup.Type: GrantFiled: February 27, 1995Date of Patent: March 4, 1997Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Claus G. Riemer, Michael A. Kerr
-
Patent number: 5599915Abstract: Sialyl Lewis.sup.x mimetic compounds are disclosed that are free of sialyl groups and glycosidically-linked fucosyl groups. These compounds exhibit about the same inhibition of selectin-medicated cellular adhesion as does sialyl Lewis.sup.x itself.Type: GrantFiled: March 21, 1995Date of Patent: February 4, 1997Assignee: The Scripps Research InstituteInventors: Chi-Huey Wong, Tetsuya Kajimoto
-
Patent number: 5597906Abstract: Carbon linked glycosyl compounds are disclosed and synthesized. The synthesis employs a blocked carbohydrate donor and a blocked glycosyl acceptor. The blocked carbohydrate donor includes an acid labile phosphite leaving group attached to the anomeric carbon. The blocked glycosyl acceptor includes an unprotected carbon susceptible to electrophilic attack. The reaction is initiated by the addition of a Lewis acid so as to activate the acid labile phosphite leaving group on the carbohydrate donor. The substitution reaction may be conducted at -78.degree. C. in a solvent which favors the formation of carbon linked glycosylation products.Type: GrantFiled: March 18, 1993Date of Patent: January 28, 1997Assignee: The Scripps Research InstituteInventors: Chi-Huey Wong, Hirosato Kondo
-
Patent number: 5585261Abstract: Aureobacterium barkerei strain KDO-37-2 (ATCC 49977) and KDO aldolase (EC 4.1.2.23) isolated therefrom are disclosed. The KDO aldolase is further disclosed to have a broad substrate specificity with respect to its reverse reaction, i.e. the condensation of aldoses with pyruvate to form a wide range of 2-keto-3-deoxy-onic acids, including 2-keto-3-deoxy-nonulosonic acid, 2-keto-3-deoxy-octulosonic acid, 2-keto-3-deoxy-heptulosonic acid, and 2-keto-3-deoxy-hexulosonic acid. In particular, 3-deoxy-D-manno-2-octulosonic acid (D-KDO), a vital component of lipopolysaccharides found in the bacterial outer membrane may be synthesized from D-arabinose and pyruvate in 67% yield.Type: GrantFiled: October 25, 1994Date of Patent: December 17, 1996Assignee: The Scripps Research InstituteInventors: Chi-Huey Wong, Takeshi Sugai, Gwo-Jenn Shen
-
Patent number: 5576174Abstract: Antibodies raised against the quaternary piperidinium haptens are shown to catalyze the aldol stereoselective addition of acetone to aldehydes using the primary benzylamine as a cofactor.Type: GrantFiled: April 5, 1995Date of Patent: November 19, 1996Assignee: The Scripps Research InstituteInventors: Jean-Louis Reymond, Yuanwei Chen
-
Patent number: 5571681Abstract: Molecules having covalent catalytic activity are identified by panning synthetic and semisynthetic combinatorial libraries on solid phase suicide substrates. In an alternative mode, mechanism-based inhibitors or affinity labels may substituted for the suicide substrate. Covalent catalysts within the combinatorial library form covalent conjugates with the suicide substrate, mechanism-based inhibitor, or affinity label. Covalent conjugates are immobilized by attachment to the suicide substrate to solid phase and are easily separated from unconjugated elements of the combinatorial library by stringent washing. Combinatorial libraries employing phagemid-display are particularly preferred since such phagemids include genetic material for identifying and amplifying conjugated catalysts. Covalent catalysts obtainable by this method include, inter alia, molecules having esterolytic activity, aldol condensation activity, .beta.-lactamase activity, glycosidase activity, RNase activity, and proteolytic activity.Type: GrantFiled: March 10, 1994Date of Patent: November 5, 1996Assignee: The Scripps Research InstituteInventor: Kim D. Janda
-
Patent number: 5563121Abstract: A peptide linkage unit is employed for joining peptide and pseudopeptide sequences, including peptides and pseudopeptides that inhibit aspartic proteinase enzymes. The peptide linkage unit includes a phosphinate methylene ammonium linkage in place of a peptidyl carboxamide bond. If the peptide linkage unit is incorporated into a peptide sequence that would otherwise serve as an aspartic proteinase substrate and if it is positioned at a cleavage site within such peptide sequence, the phosphinate methylene ammonium linkage is resistant to cleavage and serves as an exploding transition state analog of such cleavage site. When so incorporated, the phosphinate methylene ammonium linkage can bind or interfere with the active site of aspartic proteinase enzymes and inhibit its activity. Preferred inhibitors contain a phosphinic acid methylene amine group joining the P.sub.1 and P.sub.1 ' residues and have a length of 3 to about 15 amino acid residues.Type: GrantFiled: June 30, 1994Date of Patent: October 8, 1996Assignee: The Scripps Research InstituteInventors: Kim D. Janda, Peter Wirsching, Shoji Ikeda
-
Patent number: 5559000Abstract: A reaction cassette has been designed for the highly sensitive detection of the making and breaking of chemical bonds. The system may be employed as a companion device to be used in the search for antibody and other novel catalysts. The cassette also has important clinical applications in the design of diagnostic reagents. In its fully encoded format this methodology is capable of both detecting and decoding chemical events.Type: GrantFiled: January 18, 1995Date of Patent: September 24, 1996Assignee: The Scripps Research InstituteInventors: Kim D. Janda, Richard A. Lerner, Hicham Fenniri
-
Patent number: 5550246Abstract: Synthetic calicheamicin mimics employ alternative activation triggers and trigger cites and include tithers for conjugation to DNA targeting systems.Type: GrantFiled: September 7, 1994Date of Patent: August 27, 1996Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Emmanuel N. Pitsinos
-
Patent number: 5506214Abstract: Treatment of patients having multiple sclerosis with therapeutic agents containing substituted adenine derivatives such as 2-chloro-2'-deoxyadenosine is shown to markedly ameliorate the disease condition.Type: GrantFiled: July 27, 1994Date of Patent: April 9, 1996Assignee: The Scripps Research InstituteInventor: Ernest Beutler
-
Patent number: 5504206Abstract: Intermediates useful in preparing the aglycon or core structure of esperamicin are disclosed, as are methods of making and using the same.Type: GrantFiled: September 26, 1994Date of Patent: April 2, 1996Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, David A. Clark
-
Patent number: 5504222Abstract: A method for esterifying C13 deoxy taxoid intermediates employs three steps, i.e., oxygenation of the C13 deoxy taxoid intermediate to produce a C13 enone taxoid intermediate; reduction of the C13 enone to produce an alcohol; followed by esterification of the C13 alcohol. Key intermediates include C13 deoxy taxoids; C13 enone substituted taxoids; and C1-C2 cyclo carbonate esters of taxoids.Type: GrantFiled: February 8, 1994Date of Patent: April 2, 1996Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Philippe G. Nantermet, Rodney K. Guy, Hiroaki Ueno
-
Patent number: 5500432Abstract: A method for inducing apoptosis in target cells employs designed enediynes which are triggered to become chemically reactive when bound to target cells. Conversely, a method for inhibiting the induction of apoptosis employs compounds which compete with the above compounds which induce apoptosis, but which are chemically unreactive with respect to the target cells.Type: GrantFiled: April 14, 1993Date of Patent: March 19, 1996Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Andrew Hiatt, Wolfgang Wrasidlo
-
Patent number: 5500358Abstract: Catalytic antibodies are employed for catalyzing rearrangement reactions involving carbon-carbon bonds. The catalytic antibodies are generated using haptens that are transition state analogs of the such rearrangement reactions. More particularly, the haptens dispslay an electrostatic complementarity with the transition state. Since the formation of a transient positive charge in the migrating bond is a general feature of nucleophilic 1,2-shifts, it is disclosed that haptens for generating catalytic antibody directed to such reactions must incorporate such charge. Antibody catalysis of the dienone-phenol rearrangement is shown to catalyze both the hydronium ion promoted pathway and the spontaneous rearrangement pathway, indicating that the antibody stabilizes the localized positive charge of the transition state.Type: GrantFiled: August 18, 1994Date of Patent: March 19, 1996Assignee: The Scripps Research InstituteInventors: Jean-Louis Reymond, Yuanwei Chen, Richard A. Lerner